Table 4.
The ROC analysis of the six plasma biomarkers in the discrimination capacity among the groups
| Plasma biomarker | Cutoff value | Sensitivity; % | Specificity; % | AUC (95% CI) | p value |
|---|---|---|---|---|---|
| HC VS PDND | |||||
| GFAP | 187.0 | 16.33 | 97.37 | 0.5295 (0.4077–0.6513) | 0.6379 |
| NfL | 22.54 | 60.42 | 94.74 | 0.8457 (0.7658–0.9255) | < 0.0001 |
| Aβ40 | 85.28 | 36.73 | 86.84 | 0.6184 (0.5011–0.7357) | 0.0592 |
| Aβ42 | 7.644 | 28.57 | 89.47 | 0.5443 (0.4225–0.6662) | 0.4802 |
| Aβ42/40 | 0.07199 | 67.35 | 81.58 | 0.7597 (0.6568–0.8625) | < 0.0001 |
| p-tau181 | 2.244 | 38.78 | 84.21 | 0.5585 (0.4376–0.6795) | 0.3509 |
| HC VS PDD | |||||
| GFAP | 148.0 | 76.19 | 78.95 | 0.8396 (0.7280 to 0.9512) | < 0.0001 |
| NfL | 22.37 | 76.19 | 94.74 | 0.9148 (0.8302 to 0.9994) | < 0.0001 |
| Aβ40 | 107.3 | 47.62 | 73.68 | 0.5476 (0.3818 to 0.7134) | 0.5475 |
| Aβ42 | 7.985 | 33.33 | 89.47 | 0.5614 (0.3972 to 0.7256) | 0.4379 |
| Aβ42/40 | 0.07751 | 19.05 | 94.74 | 0.5282 (0.3771 to 0.6853) | 0.7217 |
| p-tau181 | 1.595 | 76.19 | 63.16 | 0.6880 (0.5319 to 0.8441) | 0.0176 |
| PDD VS PDND | |||||
| GFAP | 125.1 | 90.48 | 59.18 | 0.7765 (0.6609–0.8920) | 0.0003 |
| NfL | 53.28 | 52.38 | 91.67 | 0.6944 (0.5454–0.8435) | 0.0106 |
| Aβ40 | 107.3 | 47.62 | 83.67 | 0.6511 (0.5027–0.7996) | 0.0463 |
| Aβ42 | 7.985 | 33.33 | 81.63 | 0.5248 (0.3689–0.6806) | 0.7438 |
| Aβ42/40 | 0.06884 | 71.43 | 75.51 | 0.7046 (0.5663–0.8428) | 0.0070 |
| p-tau181 | 1.789 | 71.43 | 57.14 | 0.6190 (0.4780–0.7601) | 0.1164 |
ROC receiver operating characteristic, HC healthy control, PDND nondemented Parkinson’s disease, AUC area under the curve, CI confidence intervals, GFAP glial fibrillary acidic protein, NfL neurofilament light chain, Aβ amyloid beta, p-tau phosphorylated tau, PDD Parkinson’s disease dementia
*Bold letters indicate an acceptable or higher AUC value (> 0.7)